Summit Therapeutics Inc (SMMT)

Oct 14, 2025

News impact scoring models applied to Summit Therapeutics Inc.Quarterly Trade Summary & Trade Opportunity Analysis Reports - newser.com

Oct 14, 2025

Oct 13, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire

Oct 13, 2025

Oct 13, 2025

Will Summit Therapeutics Inc. stock continue dividend increasesQuarterly Risk Review & Real-Time Buy Zone Alerts - newser.com

Oct 13, 2025

Oct 13, 2025

Summit Therapeutics Inc. stock momentum explainedJuly 2025 Review & High Conviction Investment Ideas - newser.com

Oct 13, 2025

Oct 13, 2025

Can Summit Therapeutics Inc. hit a new high this monthBuy Signal & Accurate Entry/Exit Alerts - newser.com

Oct 13, 2025

Oct 13, 2025

Statistical indicators supporting Summit Therapeutics Inc.’s strengthBear Alert & Growth Focused Investment Plans - newser.com

Oct 13, 2025

Oct 13, 2025

Will Summit Therapeutics Inc. stock gain from lower inflationJuly 2025 Chart Watch & Weekly Watchlist for Hot Stocks - newser.com

Oct 13, 2025

Oct 12, 2025

What drives Summit Therapeutics Inc stock priceSector Performance Drivers & Rapid Capital Portfolio - earlytimes.in

Oct 12, 2025

Oct 12, 2025

APEIRON CAPITAL Ltd Takes $25.56 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat

Oct 12, 2025

Oct 12, 2025

Automated trading signals detected on Summit Therapeutics Inc.IPO Watch & Stepwise Entry and Exit Trade Signals - newser.com

Oct 12, 2025

Oct 10, 2025

Summit Therapeutics stock reaffirmed Buy at UBS ahead of ESMO data - Investing.com

Oct 10, 2025

Oct 10, 2025

Has Summit Therapeutics Inc. formed a bullish divergenceWeekly Investment Recap & Consistent Return Investment Signals - newser.com

Oct 10, 2025

Oct 10, 2025

Positive Outlook for Summit Therapeutics Driven by Anticipated HARMONi-6 Trial Success - TipRanks

Oct 10, 2025

Oct 09, 2025

Is Summit Therapeutics Inc. stock supported by strong cash flowsGold Moves & Low Drawdown Momentum Trade Ideas - newser.com

Oct 09, 2025

Oct 09, 2025

Summit Therapeutics' (SMMT) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat

Oct 09, 2025

Oct 08, 2025

Where is Summit Therapeutics (SMMT) Headed According to Analysts? - Yahoo Finance

Oct 08, 2025

Oct 06, 2025

Public Employees Retirement System of Ohio Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat

Oct 06, 2025

Oct 06, 2025

Summit Therapeutics Inc. (SMMT) Stock Analysis: Unveiling a 51.75% Potential Upside in the Biotech Arena - DirectorsTalk Interviews

Oct 06, 2025

Oct 06, 2025

How to use Fibonacci retracement on Summit Therapeutics Inc.Gap Up & Community Verified Trade Signals - newser.com

Oct 06, 2025

Oct 05, 2025

1 Monster Stock in the Making to Buy and Hold - Yahoo Finance

Oct 05, 2025

Oct 05, 2025

Published on: 2025-10-05 07:31:28 - newser.com

Oct 05, 2025

Oct 05, 2025

How to monitor Summit Therapeutics Inc. with trend dashboards2025 Market Sentiment & Community Driven Trade Alerts - newser.com

Oct 05, 2025

Oct 03, 2025

How the European Spotlight on Ivonescimab’s Phase III Data Could Shape Summit Therapeutics (SMMT) - simplywall.st

Oct 03, 2025

Oct 03, 2025

Is Summit Therapeutics Inc. forming a bottoming baseJuly 2025 Rallies & Real-Time Volume Analysis - newser.com

Oct 03, 2025

Oct 02, 2025

A Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal Investigation - Yahoo Finance

Oct 02, 2025

Oct 02, 2025

H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones - MSN

Oct 02, 2025

Oct 01, 2025

Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence - Benzinga

Oct 01, 2025

Oct 01, 2025

Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - Yahoo

Oct 01, 2025

Oct 01, 2025

Summit Therapeutics (NASDAQ:SMMT) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat

Oct 01, 2025

Sep 30, 2025

Published on: 2025-09-30 03:00:28 - newser.com

Sep 30, 2025

Sep 30, 2025

Summit Therapeutics Shares Tumble As Lung Cancer Drug Disappoints Abroad - Finimize

Sep 30, 2025

Sep 30, 2025

Published on: 2025-09-30 00:09:58 - newser.com

Sep 30, 2025

Sep 29, 2025

Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN

Sep 29, 2025

Sep 29, 2025

What analysts say about Summit Therapeutics Inc stockResistance Zone Identification & Free Stock Education Platform for New Investors - earlytimes.in

Sep 29, 2025